Although there has been a proliferation .of new cephalosporins with increased resistance to hydrolysis by gram-negative ,6-lactamases and with a concomitant increase in antibacterial spectrum, the oral agents available have been limited to cephalexin and cephradine. Cephaloglycine is no longer used because of its poor oral absorption. Cefatrizine has been reported to have an increased spectrum of activity against some gram-negative bacteria compared with that of the currently available oral drugs. We wished to evaluate the activity of this compound in comparison with cephalothin and cephalexin, as well as cefamandole and cefoxitin, whose spectrum is increased (3) (4) (5) . If cefatrizine inhibits bacterial isolates resistant to the older agents, it might provide an oral -agent to complete therapy initiated with cefoxitin or cefamandole.
(These results were presented in part at the 16th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Ill., 27-29 October 1976.)
MATERIALS AND METHODS
Cefatrizine was a gift of Bristol Laboratories. All of the other cephalosporins were obtained from their respective manufacturers. Bacterial isolates were from urine, sputum, throat, stool, and wound cultures of patients seen at the Columbia-Presbyterian Medical Center. Susceptibility tests were performed in agar by utilizing an inoculum of 105 colony-forming units applied to Mueller-Hinton agar (Baltimore Biological Laboratory). Serial twofold dilutions were prepared, and the minimum inhibitory concentration (MIC) was considered to be the lowest concentration at which there was no visible growth or less than five colonies. The MIC values of streptococci were determined in Mueller-Hinton agar supplemented with 5% sheep blood. ,B-Lactamase assays were performed by using a spectrophotometric assay at 30°C in pH 7 0.05 M phosphate buffer as previously described (3, 4) . f8-Lactamases were prepared by sonic treatment of latelogarithmic-phase bacteria. The resulting material was centrifuged at 30,000 x g for 2 h to remove cell debris. Enzymes were classified by the system of Richmond and Sykes (7) based on substrate activity and inhibition by other ,B-lactams.
RESULTS
The data in Table 1 compare the activities of cefatrizine against various strains of both grampositive and gram-negative bacteria with the activities of cephalothin, cephalexin, cefamandole, and cefoxitin. Cefatrizine was less active against Staphylococcus aureus than cephalothin or cefamandole, with a concentration of 0.4 ,ug of cefatrizine per ml required to inhibit 50% of isolates, compared with 0.1 jig/ml for the latter two agents. But cefatrizine was two-to. fourfold more active against S. aureus than were cephalexin or cefoxitin. The activity of* cefatrizine against Staphylococcus epidermidis was similar to its activity against S. aureus, but cefatrizine was distinctly more active than cephalexin or cefoxitin. A total of90% of isolates were inhibited by 1.6 ,ug of cefatrizine per ml, compared with 50% inhibited by cefoxitin and 40% inhibited by cephalexin at this same concentration. Although cefatrizine was two-to fourfold more active than the other agents against Streptococcus faecalis, eightfold difference between the MICs and the minimal bactericidal concentrations for five isolates tested in broth. Cefatrizine had activity similar to that of cefamandole against most of the Escherichia coli isolates tested. It inhibited the majority of cephalothin-susceptible E. coli at concentrations two to fourfold below the concentrations required with cephalothin or cephalexin. A total of 80% of E. coli isolates were inhibited by 25 ,tg of cefatrizine per ml, but cefoxitin inhibited 97% and cefamandole inhibited 87% at this concentration. Against Klebsiella, cefatrizine had activity similar to that of the other agents, with minor differences among the individual isolates. Cefatrizine inhibited most Enterobacter aerogenes at concentrations of 12.5 ,ig/ml or less, but some Enterobacter cloacae and Enterobacter hafnia were fully resistant (MICs, >200 ,ug/ml). Cefatrizine was more active than cephalothin, cephalexin, or cefoxitin against Enterobacter spp., but less active than cefamandole. Cefatrizine was more active than cephalothin, cephalexin, or cefoxitin, against Citrobacter freundii, but less active than cefamandole. It inhibited the majority of Citrobacter isolates at concentrations of 12.5,ug/ml. It also inhibited all Citrobacter diversus (12 isolates at concentrations of 6.3 ytg/ml or less. All of the agents inhibited the majority of the Proteus mirabilis strains tested. The minor differences shown in Table 1 are due to only a few strains and do not indicate a clear superiority of any compound. The indole-positive Proteus included P. morganii, P. rettgeri, and P. vulgaris. Although some isolates resistant to cephalothin and cephalexin were inhibited by cefatrizine, the MICs of cefatrizine for the majority of the isolates were greater than 25 ,ug/ml whereas at this concentration cefoxitin inhibited more than 90% of the isolates and cefamandole inhibited 65%. Similarly, cefatrizine was no more active than either cephalothin or cephalexin against strains of Providencia stuartii, many of which were inhibited by cefoxitin and cefamandole. Cefatrizine inhibited 60% of Serratia marcescens isolates at 50 ,ug/ml, whereas none of the isolates was inhibited by 400 ,tg of cephalothin or cephalexin per ml. Cefatrizine was more active than cefamandole, but less active than cefoxitin, against Serratia. Cefatrizine had excellent activity against Salmonella species, including S. typhi, S. typhimurium, S. heidelberg, and S. enteritidis. It inhibited 81% of the isolates at concentrations of 6.3 ,ug/ml or less. All S. typhi (4 isolates) and S. typhimurium (8 A direct comparison of the activities of cefatrizine and three /8-lactamase-stable cephalosporins is given in Table 2 . All of the isolates were resistant to cephalothin (MICs, >400 ,ug/ml) and were 83-lactamase-producing strains as determined by the Glaxo chromogenic cephalosporin assay. Except for a C. freundii strain and an S. typhi isolate, the MICs were 50 tig/ml or greater.
In contrast, the MICs for the other three agents in a number of instances were 3.1 to 25 ,ug/ml, concentrations which could be achieved in clinical practice.
The activity of cefatrizine against E. coli, Klebsiella, Salmonella, and Shigella appeared to be related to its stability against the ,B-lactamases present in these species (Table 3) . It was not hydrolyzed by the most common plasmidmediated fi-lactamase (Richmond class III) present in E. coli and Salmonella. It was also resistant to hydrolysis by the less common plasmid-mediated /3-lactamase in S. sonnei, which hydrolyzes the isoxazolyl penicillins as readily as it does ampicillin (Table 3) . Cefatrizine was not hydrolyzed by S. aureus f8-lactamases.
In contrast, although cefatrizine was not hydrolyzed by the inducible 3-lactamases (cephalosporinases) of most Serratia, Providencia, Acinetobacter, and Citrobacter, it did not inhibit these strains. Cefatrizine had an MIC of 100 jig/ml against a Providencia strain which did not hydrolyze cefatrizine. Cefamandole, which was hydrolyzed by the strain, inhibited this Providencia at 3.1 tLg/ml. A similar situation was found with an Acinetobacter isolate. DISCUSSION Earlier publications (1, 2, 6, 8, 9) have suggested that cefatrizine is an agent that would extend the spectrum of oral and parenteral cephalosporins, but these studies compared its activity with that of older agents and not with that of cefamandole, cefuroxime, and cefoxitin, which have an expanded spectrum of activity (3) (4) (5) . Although cefatrizine has excellent stability com- 
